Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Capricor Therapeutics Inc...

    NASDAQ: CAPR · Real-Time Price · USD
    7.71
    -0.25 (-3.14%)
    At close: Aug 18, 2025, 3:59 PM
    7.70
    -0.19%
    After-hours: Aug 18, 2025, 07:12 PM EDT
    -3.14%
    Bid 7.7
    Market Cap 352.71M
    Revenue (ttm) 17.36M
    Net Income (ttm) -55.07M
    EPS (ttm) -1.59
    PE Ratio (ttm) -4.85
    Forward PE -19.37
    Analyst Buy
    Ask 7.8
    Volume 1,049,243
    Avg. Volume (20D) 2,650,874
    Open 7.85
    Previous Close 7.96
    Day's Range 7.68 - 8.00
    52-Week Range 3.94 - 23.40
    Beta 0.59

    About CAPR

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CAPR
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for CAPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Capricor Therapeutics Inc. is scheduled to release its earnings on Nov 12, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    +12.39%
    Capricor Therapeutics shares are trading higher af... Unlock content with Pro Subscription
    2 weeks ago
    +21.36%
    Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.
    news image

    20 hours ago · seekingalpha.com

    Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

    Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2025 Earnings Conference August 13, 2025 4:30 PM ET Company Participants Anthony J. Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, Presid...

    news image

    1 week ago · businesswire.com

    Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Class Action Filing and Encourages Investors to Contact the Firm

    NEW YORK--(BUSINESS WIRE)---- $CAPR #CAPR--The law firm of Kirby McInerney LLP reminds investors who purchased Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:CAPR) securities to con...

    news image

    2 weeks ago · benzinga.com

    What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

    In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Pr...

    news image

    4 weeks ago · businesswire.com

    Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

    LOS ANGELES--(BUSINESS WIRE)---- $CAPR--Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR.

    news image

    4 weeks ago · businesswire.com

    Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

    NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Capricor Therapeutics, ...

    news image

    4 weeks ago · businesswire.com

    Gibbs Mura Announces a Securities Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR); CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

    OAKLAND, Calif.--(BUSINESS WIRE)---- $CAPR #CAPR--Gibbs Mura announces that a class action lawsuit has been filed on behalf of Capricor Therapeutics, Inc. (CAPR) investors.

    news image

    1 month ago · businesswire.com

    CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

    LOS ANGELES--(BUSINESS WIRE)---- $CAPR--CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

    Add to Watchlist